Transcript of Speech and Q&A Conference Call Q2 - MorphoSys

treatment of Alzheimer’s disease, the data is of limited relevance to gantenerumab. The main
reason for this is that the two antibodies are being tested in different patient populations.
Whereas the ongoing phase 3 trials of bapineuzumab are being conducted in mild- to
moderate Alzheimer’s disease patients, gantenerumab is being developed in prodromal, or
early stage sufferers. This is an important difference, which reflects current understanding of
the disease, namely that once symptoms appear, it may be too late for therapeutic
intervention, and that the best chance of treatment is to intervene at the earliest possible
opportunity, to prevent the damaging effects associated with the build-up of �-amyloid
plaques.
Gantenerumab is the most advanced antibody being developed in this way. Needless to say,
the medical need and commercial opportunity are enormous.
Slide 7: Partnered Pipeline: Selected Phase 2 Programs - Outlook
While gantenerumab is the first partnered compound to enter late-stage clinical development,
several programs have the potential to progress to this stage fairly quickly. More specifically,
various active phase 2 studies for three Novartis compounds - including BHQ880 in cancer
and BYM338 in musculoskeletal diseases – as well as the Janssen compound CNTO888 in
IPF are scheduled for completion by the end of this year. As a result, we could see clinical
data being published by our partners for a number of these studies. Success in Phase 2
could also mean of course additional Phase 3 programs adding maturity to our pipeline.
Slide 8: Q2 2012: Pipeline Update – Partnered Pipeline (II)
Regarding other partnered programs, there were several developments during the second
quarter.
First, our partner OncoMed presented data on both currently ongoing HuCAL antibody
programs during and after the end of the quarter. Most importantly, phase 1 data on the anti
Notch antibody OMP-59R5 presented at ASCO showed that the antibody was generally safe
and a maximum tolerated dose was established. For OMP-18R5 OncoMed published
preclinical data demonstrating potent anti-cancer activity and synergistic activity with
standard-of-care chemotherapeutic agents of the antibody in multiple human tumor models.
Second, as reported on clinicaltrials.gov, a phase 2 study by Novartis evaluating the safety,
tolerability and efficacy of BYM338 in patients with sporadic inclusion body myositis has been
completed. This HuCAL antibody is also the subject of a further two phase 2 trials.
Third, our partner Bayer HealthCare received orphan drug status in the US for BAY94-9343
for the treatment of mesothelioma. This drug candidate is an antibody-drug conjugate
comprising a HuCAL antibody against the target mesothelin, linked to a maytansinoid toxin.
The program is currently in Phase 1 development.
To complete the updates on partnered programs, our partner Janssen has reported
commencing a new phase 2 trial of the HuCAL antibody CNTO1959. In this study,
CNTO1959 will be compared with the marketed antibody Stelara in about 250 rheumatoid
MorphoSys AG Q2 2012 Conference Call Manuscript Page 3 of 17